![PDF) Genetic Interactions with Age, Sex, Body Mass Index, and Hypertension in Relation to Atrial Fibrillation: The AFGen Consortium PDF) Genetic Interactions with Age, Sex, Body Mass Index, and Hypertension in Relation to Atrial Fibrillation: The AFGen Consortium](https://i1.rgstatic.net/publication/319651872_Genetic_Interactions_with_Age_Sex_Body_Mass_Index_and_Hypertension_in_Relation_to_Atrial_Fibrillation_The_AFGen_Consortium/links/59b8150a0f7e9bc4ca389c79/largepreview.png)
PDF) Genetic Interactions with Age, Sex, Body Mass Index, and Hypertension in Relation to Atrial Fibrillation: The AFGen Consortium
![PDF) Updated European Heart Rhythm Association Practical Guide on the use of non-Vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation PDF) Updated European Heart Rhythm Association Practical Guide on the use of non-Vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation](https://i1.rgstatic.net/publication/281521114_Updated_European_Heart_Rhythm_Association_Practical_Guide_on_the_use_of_non-Vitamin_K_antagonist_anticoagulants_in_patients_with_non-valvular_atrial_fibrillation/links/5683ac7908ae1e63f1f1b5f2/largepreview.png)
PDF) Updated European Heart Rhythm Association Practical Guide on the use of non-Vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation
![Современные аспекты антикоагулянтной терапии при катетерной аблации фибрилляции предсердий – тема научной статьи по клинической медицине читайте бесплатно текст научно-исследовательской работы в электронной библиотеке КиберЛенинка Современные аспекты антикоагулянтной терапии при катетерной аблации фибрилляции предсердий – тема научной статьи по клинической медицине читайте бесплатно текст научно-исследовательской работы в электронной библиотеке КиберЛенинка](https://cyberleninka.ru/viewer_images/18086583/f/1.png)
Современные аспекты антикоагулянтной терапии при катетерной аблации фибрилляции предсердий – тема научной статьи по клинической медицине читайте бесплатно текст научно-исследовательской работы в электронной библиотеке КиберЛенинка
![Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study - The Lancet Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study - The Lancet](https://www.thelancet.com/cms/asset/0fbd577d-c99c-4d29-b95b-d235589de345/gr1.jpg)
Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study - The Lancet
![A Randomized Controlled Trial Comparing Apixaban With the Vitamin K Antagonist Phenprocoumon in Patients on Chronic Hemodialysis: The AXADIA- AFNET 8 Study | Circulation A Randomized Controlled Trial Comparing Apixaban With the Vitamin K Antagonist Phenprocoumon in Patients on Chronic Hemodialysis: The AXADIA- AFNET 8 Study | Circulation](https://www.ahajournals.org/cms/asset/bcaa7454-a536-453c-bcb9-e80a224a4389/circulationaha.122.062779.fig01.jpg)